Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

Phase 3

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Bortezomib
Drug: Dexamethasone
Drug: Isatuximab

First Posted Date: 2018-08-06

Last Posted Date: 2023-05-12

Lead Sponsor: University of Heidelberg Medical Center

Target Recruit Count: 662

Registration Number: NCT03617731

Locations: 🇩🇪
Helios Klinikum Bad Saarow, Klinik für Hämatologie, Onkologie und Palliativmedizin, Bad Saarow, Germany
🇩🇪
Uniklinik RWTH Aachen, Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation, Aachen, Germany
🇩🇪
Klinikum Darmstadt, Med. Klinik V, Hämatologie/Onkologie, Darmstadt, Germany

and more 70 locations

The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD

Phase 2

Active, not recruiting

Conditions: Hodgkin's Lymphoma

Interventions: Drug: Bendamustine
Drug: Gemcitabine
Drug: Dexamethasone
Diagnostic Test: PET/CT
Procedure: Autologous Stem Cell Transplant

First Posted Date: 2018-08-06

Last Posted Date: 2024-04-12

Lead Sponsor: Polish Lymphoma Research Group

Target Recruit Count: 115

Registration Number: NCT03615664

Locations: 🇵🇱
Klinika Hematologii i Transplantologii, Uniwersyteckie Centrum Kliniczne, Gdańsk, Poland
🇵🇱
Szpitale Pomorskie Sp. z o.o., Gdynia, Poland
🇵🇱
Oddział Chorób Wewnętrznych i Chemioterapii Onkologicznej, Samodzielny Publiczny Szpital Kliniczny im. A.Mielęckiego, Katowice, Poland

and more 10 locations

A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation

Phase 2

Withdrawn

Conditions: Multiple Myeloma

Interventions: Drug: Ixazomib
Drug: Thalidomide
Drug: Dexamethasone

First Posted Date: 2018-08-01

Last Posted Date: 2020-01-14

Lead Sponsor: Takeda

Registration Number: NCT03608501

Locations: 🇧🇷
Instituto COI de Educacao e Pesquisa, Rio de Janeiro, RJ, Brazil
🇧🇷
Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil
🇧🇷
Universidade Estadual de Campinas UNICAMP - HEMOCENTRO, Campinas, SP, Brazil

and more 3 locations

Dexamethasone Added to Intensive Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML)

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Dexamethasone

First Posted Date: 2018-08-01

Last Posted Date: 2024-10-29

Lead Sponsor: French Innovative Leukemia Organisation

Target Recruit Count: 120

Registration Number: NCT03609060

Locations: 🇫🇷
Hôpital Haut Levêque- CFM -Hématologie Clinique Et Thérapie Cellulaire, Pessac, France
🇫🇷
CHU Hautepierre - Hématologie, Strasbourg, France
🇫🇷
CH de Béziers - Hématologie, Béziers, France

and more 22 locations

Dexamethasone Versus Dexmedetomidine as Adjuvants for Nerve Blocks

Not Applicable

Completed

Conditions: Upper Extremity Injury
Pain, Acute
Pain, Postoperative

Interventions: Drug: Dexamethasone
Drug: Dexmedetomidine

First Posted Date: 2018-08-01

Last Posted Date: 2019-05-01

Lead Sponsor: University of Chile

Target Recruit Count: 120

Registration Number: NCT03610893

Locations: 🇨🇱
Hospital Clínico Universidad de Chile, Santiago, Metropolitana, Chile

Iontophoresis With Dexamethasone and Physical Therapy to Treat Apophysitis of the Knee in Pediatrics

Phase 2

Terminated

Conditions: Apophysitis; Juvenile

Interventions: Drug: Dexamethasone Sodium Phosphate
Procedure: Physical Therapy
Procedure: Iontophoresis

First Posted Date: 2018-07-31

Last Posted Date: 2024-03-06

Lead Sponsor: Children's Health System, Inc.

Target Recruit Count: 45

Registration Number: NCT03606980

Locations: 🇺🇸
CHKD Sports Medicine Physical Therapy - Oakbrooke, Chesapeake, Virginia, United States
🇺🇸
CHKD Sports Medicine Physical Therapy - Tech Center, Newport News, Virginia, United States
🇺🇸
CHKD Sports Medicine Physical Therapy - Loehmann's Plaza, Virginia Beach, Virginia, United States

and more 2 locations

An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Daratumumab
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2018-07-31

Last Posted Date: 2021-04-28

Lead Sponsor: Nantes University Hospital

Target Recruit Count: 50

Registration Number: NCT03606577

Locations: 🇫🇷
CHRU Hôpital du Haut Lévêque, Pessac, France
🇫🇷
CHRU - Hôpital de Pontchaillou, Rennes, France
🇫🇷
CH de Lyon Sud, Lyon, France

and more 9 locations

Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Recurrent Plasma Cell Myeloma

Interventions: Drug: Carfilzomib
Drug: Dexamethasone
Biological: Nivolumab
Biological: Pelareorep

First Posted Date: 2018-07-30

Last Posted Date: 2023-10-06

Lead Sponsor: Emory University

Target Recruit Count: 23

Registration Number: NCT03605719

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States